Clinical Trials

Trait Absorption Predicts Ketamine Response in TRD: MUSIK Trial Insights

Exploratory results from the MUSIK RCT suggest that the personality trait 'absorption' enhances ketamine's antidepressant effects in treatment-resistant depression, especially when paired with music-based support.

Published November 14, 2026 Read 4 min 830 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Trait Absorption Strongly Predicts Ketamine Response in TRD

Results from the MUSIK randomized clinical trial (NCT04701866) indicate that individuals with higher levels of the personality trait 'absorption' experience significantly greater antidepressant effects from ketamine therapy for treatment-resistant depression (TRD), particularly when paired with music-based support. Trait absorption refers to a person's tendency to become deeply immersed in sensory, imaginative, or emotional experiences. In this exploratory analysis, higher baseline absorption scores were robustly associated with pre- to post-treatment improvements in depression (correlation coefficient r = .721, p ≤ .002), anxiety (r = .546), and mystical-type experiences (r = .528–.637), as measured by the Mystical Experience Questionnaire.

The MUSIK trial, conducted at two Montreal hospitals, randomized 32 adults with severe TRD to receive either music (n = 15) or matched non-music (mindfulness-based) support (n = 17) during six intravenous ketamine infusions (0.5 mg/kg over 40 minutes) across four weeks. Outcome assessors were blinded to group allocation, ensuring rigorous assessment of clinical endpoints.

Mechanisms: Drug-Context Interactions and Mystical Experiences

Trait absorption appears to amplify the therapeutic effects of ketamine via increased susceptibility to immersive, emotionally salient experiences during infusions, especially in a music-rich environment. The study found that individuals with higher absorption not only reported greater reductions in depressive symptoms and suicidality but also experienced more pronounced mystical-type effects—a phenomenon previously observed with serotonergic psychedelics like psilocybin, but not systematically studied with ketamine until now.

Multilevel modeling revealed a three-way interaction between time, treatment group, and absorption: music-based support was associated with steeper declines in depressive symptoms among high-absorption participants (p < .001). This suggests that the therapeutic context—specifically, the use of evocative music—may synergize with individual psychological traits to maximize ketamine’s clinical benefit.

Notably, this trial is among the first to empirically demonstrate that non-pharmacological factors, such as personality and environmental context, can meaningfully modulate ketamine’s antidepressant efficacy. This insight challenges the prevailing notion that ketamine’s effects are primarily pharmacological and highlights the importance of integrating psychotherapeutic and contextual elements into ketamine-assisted therapy protocols.

Policy and Research Implications: Toward Personalized Ketamine Therapy

These findings, if replicated in larger and more diverse cohorts, could have significant implications for patient selection and the design of ketamine-assisted therapy in clinical practice. Screening for trait absorption using validated psychometric tools could help identify patients most likely to benefit from immersive, music-supported ketamine interventions, potentially improving outcomes and optimizing resource allocation in mental health services.

For policymakers and clinical guideline developers, the MUSIK trial underscores the need to consider both pharmacological and non-pharmacological variables when evaluating the safety, efficacy, and cost-effectiveness of psychedelic-assisted therapies. The results also suggest that regulatory frameworks should accommodate flexible, individualized approaches to supportive care (e.g., music, mindfulness, or other modalities) rather than mandating a one-size-fits-all protocol.

From a research perspective, the study highlights the value of investigating drug-context interactions and individual difference variables in ongoing and future trials of ketamine and other psychedelic agents. Importantly, the MUSIK trial’s design—pairing a rigorous randomized controlled structure with nuanced psychological assessments—sets a precedent for how future studies might be structured to elucidate these complex interactions.

Risks, Unknowns, and Limitations

While the MUSIK trial offers promising insights, several limitations and unknowns remain. The study’s sample size (n = 32) is relatively small, and the findings are exploratory; replication in larger, multi-site trials is essential before clinical recommendations can be made. The generalizability of results to populations outside the Montreal hospital setting or to individuals with lower baseline absorption is unknown.

Additionally, while higher absorption predicted greater benefit, it is unclear whether individuals with low absorption might require alternative therapeutic supports or dosing strategies to achieve comparable outcomes. There is also a need to better understand the potential risks associated with intensified mystical experiences, such as emotional overwhelm or the emergence of challenging psychological material, particularly in vulnerable patients.

Finally, the study did not assess long-term outcomes beyond the four-week intervention, leaving open questions about the durability of ketamine’s antidepressant effects as modulated by absorption and context.

Looking Ahead: Individualized Approaches and Future Directions

The MUSIK trial’s results suggest a future in which ketamine-assisted therapy for TRD is tailored not only to diagnostic criteria but also to individual psychological traits and contextual preferences. If further research supports these findings, screening for absorption and offering personalized support modalities could become standard practice, potentially improving both efficacy and safety in psychedelic-assisted mental health care.

As the field moves toward regulatory approval and broader clinical adoption of ketamine and other psychedelic therapies, integrating personality assessment and context-sensitive interventions may help optimize outcomes and minimize risks. The MUSIK trial’s approach—combining rigorous clinical methodology with an appreciation for the nuances of individual experience—offers a model for future research and clinical innovation in psychedelic medicine.

Reviewed by Dr. Alex Garel, MD, PhD, on 2026-11-18. How we research: This analysis draws directly from the MUSIK trial publication (OpenAlex W7230749341), the clinical trial registry (NCT04701866), and primary data from the investigators. All clinical and policy claims are substantiated with first-party sources.

Primary source: https://openalex.org/W7230749341 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.